PMS-ROPINIROLE TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

ROPINIROLE (ROPINIROLE HYDROCHLORIDE)

Saatavilla:

PHARMASCIENCE INC

ATC-koodi:

N04BC04

INN (Kansainvälinen yleisnimi):

ROPINIROLE

Annos:

2MG

Lääkemuoto:

TABLET

Koostumus:

ROPINIROLE (ROPINIROLE HYDROCHLORIDE) 2MG

Antoreitti:

ORAL

Kpl paketissa:

10/100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0132618004; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2009-07-22

Valmisteyhteenveto

PRODUCT MONOGRAPH
PR
PMS-ROPINIROLE
Ropinirole Hydrochloride Tablets, House
0.25 mg, 0.5 mg 1.0 mg, 2.0 mg, 5.0 mg ropinirole
(as ropinirole hydrochloride)
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Ave. Royalmount, Suite 100
June 12, 2017
Montreal, Quebec
H4P 2T4
www.pharmascience.com
SUBMISSION CONTROL NO: 206310
_pms-ROPINIROLE Product Monograph Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
4
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
21
DOSAGE AND ADMINISTRATION
..............................................................................
23
OVERDOSAGE
................................................................................................................
24
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 25
STORAGE AND STABILITY
.........................................................................................
28
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 28
PART II: SCIENTIFIC INFORMATION
................................................................................
30
PHARMACEUTICAL INFORMATION
.........................................................................
30
CLINICAL TRIALS
......................................................................